Breaks Categories: News

WednesdayJan 11, 2023 9:57 am

BioMedNewsBreaks — MetAlert Inc. (MLRT), TrakTec Sign Heads of Terms Agreement for Upcoming Acquisition

MetAlert (OTC: MLRT), a pioneer in location-sensitive, health-monitoring devices and wearable technology products for remote patient monitoring, signed a Heads of Terms agreement with TrakTec outlining details about the previously announced acquisition. The agreement noted that MLRT would acquire the location-awareness technology company in a cash and stock deal worth $4.5 million. The agreement also notes that the acquisition should be closed on or before March 17, 2023, and will include TrakTec’s active paying subscriber base, police department contracts, commercial ready tracking products, and backend platform and mobile app. In addition, the agreement noted that key hires would include board…

Continue Reading

TuesdayJan 10, 2023 1:49 pm

BioMedNewsBreaks – MetAlert Inc. (MLRT) Featured on ‘Gametime with Sequire’

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products for remote patient monitoring, was featured in a recent interview with Sequire Spotlight. In the program, MetAlert’s CEO Patrick Bertagna joined Host Carmel Fisher to discuss the company’s business model and goals heading into the near future. “We’re a medical device/technologies company. We cater to a specific segment of the population – people with cognitive memory disorders such as Alzheimer’s, dementia, autism, traumatic brain injury,” Bertagna said. “And most of these people can’t use conventional type of technologies. So, we’ve developed a suite of products and…

Continue Reading

TuesdayJan 10, 2023 11:48 am

BioMedNewsBreaks – QSAM Biosciences Inc. (QSAM) Releases Shareholder Letter Outlining 2022 Updates, 2023 Milestone Goals

QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and related diseases, has provided key updates and milestone goals in a shareholder letter; the letter is from QSAM Biosciences executive chair and cofounder C. Richard Piazza and CEO and cofounder Douglas Baum. The letter noted that QSAM is developing its lead therapeutic radiopharmaceutical drug candidate, CycloSam, to treat cancer that has either originated in the bone or has metastasized to the bone from the breast, prostate, lung or other organs. During 2022, CycloSam received rare pediatric disease designation for the…

Continue Reading

TuesdayJan 10, 2023 11:35 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Key Milestones, 2023 Business Outlook

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today outlined key accomplishments from 2022 and provided a business update and catalysts for 2023. “Over the course of 2022, we strengthened our position as a leader in rare cannabinoid R&D, creating a unique offering as the only company that has the breadth and depth in cannabinoid drug research, development and significant manufacturing know-how,” said Eric A. Adams, InMed president and CEO. “Despite the many economic pressures affecting businesses on a global scale, including challenging capital markets, particularly in biotech, InMed…

Continue Reading

TuesdayJan 10, 2023 10:53 am

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Begins Trading on Next-Gen Marketplace

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, announced that today at 10 a.m. EST, the company will start trading on Upstream under the ticker symbol JUPW. A revolutionary trading app for digital securities and NFTs, Upstream is powered by Horizon Fintex and MERJ Exchange Limited. The company noted that a digital collectible NFT commemorating the dual listing would be available for Upstream participants to claim using the code: JUPW. Through Upstream, investors around the world can invest in JUPW by downloading the Upstream app from their preferred app store and creating an account. Transactions…

Continue Reading

MondayJan 09, 2023 11:56 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announced the incorporation of a new subsidiary to capitalize on drug development incentives in Australia. The company also announced its expanded focus to investigate other products addressing acute medical needs due to substances of abuse such as alcohol, as well as the appointments of Dr. Jeremy Chataway, Dr.Ashwin Dhanda and Dr. Anh Lê to its scientific and clinical expert committee. “We are excited about the incorporation of FSD Pharma Australia, where…

Continue Reading

MondayJan 09, 2023 10:36 am

BioMedNewsBreaks — MetAlert Inc. (MLRT) Featured in Ludlow Research Analyst Brief

MetAlert (OTC: MLRT), a pioneer in location-sensitive, health-monitoring devices and wearable technology products for remote patient monitoring, spotlighted in a recent Q&A analyst report released by Ludlow Research. In the article, MLRT representations respond to questions, providing an overview of the company and discussing specific topics investors and shareholders might be interested in. The report delved into the company’s recent restructuring, name change and ticker symbol change, with the company stating that “we waited patiently to do this until we had a clean balance sheet and were prepared to take the company to the next level.” The report noted that…

Continue Reading

MondayJan 09, 2023 10:28 am

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Status Update on Clinical Development Programs

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), is discussing upcoming priorities and near-term milestones regarding the status of its two clinical programs aimed at addressing multiple mental health conditions: CYB003 and CYB004. Designed for the treatment of Major Depressive Disorder (“MDD”), CYB003 is currently in a phase 1/2a clinical trial. CYB003 is a deuterated psilocybin analog. CYBN anticipates releasing an interim readout from the trial by the end of February 2023, which will provide an initial understanding of the safety and pharmacokinetic (“PK”) profile of the substance in humans. This interim data will…

Continue Reading

FridayJan 06, 2023 11:36 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) to Participate in Upcoming J.P. Morgan Healthcare Conference

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has announced that key executives will be attending the 41st annual J.P. Morgan Healthcare Conference. Scheduled for Jan. 9–12, 2023, in San Francisco, California, the conference has become largest and most informative healthcare investment symposium in the industry. The event is known for gathering together global industry leaders with officials from emerging fast-growth companies along with innovative technology creators and members of the investment community. FSD Pharma director and CEO Dr. Lakshmi…

Continue Reading

FridayJan 06, 2023 10:10 am

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Study Results Indicating Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is reporting additional results from a preclinical in vivo proof-of-concept study. The study evaluated BVXV’s innovative inhaled nanosized antibody (“NanoAb”) COVID-19 therapy; results indicate that the presence of the SARS-COV-2 virus in the lungs of hamsters treated with BiondVax’s NanoAb was “virtually eliminated” and significantly less than the amount of virus detected in the placebo group. Specifically, hamsters infected with SARS-COV-2 that were treated with BiondVax’s inhaled anti-COVID-19 nanosized antibodies had more than 30 times…

Continue Reading